Compare Grab Holdings Ltd. (GRAB) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Grab Holdings Ltd. vs Twist Bioscience Corp — how do they compare? Grab Holdings Ltd. trades at $3.19 (market cap $12.72B), while Twist Bioscience Corp trades at $158.85 (market cap $10.08B). The key difference: Grab Holdings Ltd. is the larger of the two by market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Grab Holdings Ltd. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Grab Holdings Ltd. for 94 Days and Twist Bioscience Corp for 27 Days on average.
| GRAB | TWST | |
|---|---|---|
Market Cap | $12.72B | $10.08B |
Volume | 65,352,859 | 4,229,037 |
Sector | Technology | Health |
52-Week High | $6.17 | $205.00 |
52-Week Low | $2.80 | $25.45 |
Typical Hold Time | 94 Days | 27 Days |
Enterprise Value | $8.46B | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GRAB trades at $3.08, up 0.33% with bearish technical signals but strong fundamentals. The company achieved profitability in 2025 with $268M net income and has beaten earnings estimates for three consecutive quarters. Recent developments include a $1.49B acquisition of Atome Financial and $30M in insider buying by the CEO, signaling confidence in growth prospects despite recent stock pressure.
GRAB presents a compelling turnaround story with accelerating revenue growth and margin expansion. The risk-reward appears favorable given the 92% analyst buy rating, though investors should monitor integration risks from the Atome acquisition and competitive pressures in Southeast Asian markets that could impact future profitability.
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Grab Holdings Ltd.
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
